Project Grant R21CA292033
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $419K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Toledo, OH 43614, USA
Similar Awards
- The University of Toledo received a $636,185 Project Grant award from the National Cancer Institute under the Cancer Biology Research federal grant program (CFDA 93.396) to conduct research on dormancy-mimicking strategies to inhibit prostate cancer metastasis progression and recurrence. The research aims to investigate how disseminated prostate cancer cells can remain dormant/quiescent in distant organs, enabling them to escape treatments and later reactivate, leading to metastasis and...
- Federal Grant Award Summary The University of Toledo received a $153,000 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2027. This award supports fundamental research aimed at optimizing the "knocksideways" technique to visualize and analyze interactions between protein subcomplexes, specifically focusing on the MAD1:MAD2 complex and its role in the spindle assembly checkpoint. The...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $521,002 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), with an award date of March 26, 2026, and completion date of February 28, 2031. The grant funds development and validation of a bone metastasis-on-a-chip microphysiological platform designed to advance understanding of prostate cancer metastasis to bone, which occurs in over 80% of...
- Federal Grant Award Summary The University of Toledo received a Project Grant award of $559,543 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 5, 2025, through August 31, 2028. The award supports fundamental research investigating the overlap between mitotic and ferroptotic cellular pathways through the development and characterization of novel hybrid small molecule inhibitors....
- Federal Project Grant Award Summary The University of Tennessee Health Science Center received a $658,561 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 7, 2025, with a completion date of July 31, 2030. This award supports research focused on targeted MDM2 (Murine Double Minute 2) degradation as an improved therapeutic strategy for triple-negative breast cancer (TNBC). The project centers on optimization and...
- Federal Grant Award Summary Temple University received a $177,209 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 18, 2025, with a completion date of June 30, 2027. The award supports research aimed at developing fluorine-thiol displacement reaction (FTDR)-stapled peptide probes to target C-MYC, an undruggable transcription factor implicated in castration-resistant prostate cancer (CRPC) progression. The research...
- Federal Project Grant Award Summary The University of Pittsburgh received a $435,788 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This award supports the development of active site-directed inhibitors and bifunctional degraders targeting mutant isocitrate dehydrogenase (IDH1 and IDH2) enzymes implicated in progressive gliomas and hematological malignancies. The research addresses a...
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $393,872 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2027. The award supports research and development of therapeutic antibody-drug conjugates (ADCs) targeting leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) and the receptor tyrosine kinase MET to overcome tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...